biOasis Technologies Inc. announced its slate of nominees to the board of directors for election at the annual general meeting of shareholders (the "Meeting") on Sept. 21, 2017. The slate is comprised of four current directors and three new nominees. The biOasis management team has nominated accomplished biopharmaceutical executives Nancy Stagliano, Ph.D., Deborah Rathjen, Ph.D. and Maha Radhakrishnan, M.D. for election to the Board at the Meeting. biOasis founder Mr. Rob Hutchison will step down as chairman of the board on Dec. 31, 2017. Dr. Stagliano has a notable track record of leadership and innovation in the biotech industry. As a chief executive officer with three consecutive therapeutics company successes, Dr. Stagliano has demonstrated a strong formula for drug discovery and development, fundraising and M&A. Dr. Stagliano transformed iPierian Inc. from a platform to product company, resulting in its acquisition by Bristol-Myers Squibb and subsequent development of its neurodegenerative disease antibody by Biogen. Dr. Stagliano's most recent company, True North Therapeutics, was acquired in June 2017 by Bioverativ based on the discovery and development of a breakthrough therapy for complement-mediated orphan diseases. Dr. Rathjen has proven to be a skilled dealmaker and builder of alliances with her work on the Bionomics and Merck collaborations related to Alzheimer's disease and other neurodegenerative and psychiatric diseases with the goal to improve cognitive dysfunction in neurodegeneration. The company also has an oncology pipeline. Dr. Radhakrishnan brings significant global, medical and scientific expertise via her medical affairs leadership roles. Her relevant experience includes strategic collaborations in research, with the most recent example for advanced imaging between Bioverativ and Invicro. Dr. Radhakrishnan also has extensive product launch experience including blockbuster treatments at BMS, Cephalon, Biogen and Bioverativ. Dr. Radhakrishnan has significant experience across a broad range of therapeutic areas, including several diseases and disorders within CNS such as multiple sclerosis, Alzheimer's disease, neuropathic pain, spinal muscular atrophy, schizophrenia, major depression, bipolar disorder, migraine, progressive supranuclear palsy and front temporal dementia.